ondansetron has been researched along with Brugada Syndrome in 1 studies
Ondansetron: A competitive serotonin type 3 receptor antagonist. It is effective in the treatment of nausea and vomiting caused by cytotoxic chemotherapy drugs, including cisplatin, and has reported anxiolytic and neuroleptic properties.
Brugada Syndrome: An autosomal dominant defect of cardiac conduction that is characterized by an abnormal ST-segment in leads V1-V3 on the ELECTROCARDIOGRAM resembling a right BUNDLE-BRANCH BLOCK; high risk of VENTRICULAR TACHYCARDIA; or VENTRICULAR FIBRILLATION; SYNCOPAL EPISODE; and possible sudden death. This syndrome is linked to mutations of gene encoding the cardiac SODIUM CHANNEL alpha subunit.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Lee, JH | 1 |
| Park, YH | 1 |
| Kim, JT | 1 |
| Kim, CS | 1 |
| Kim, HS | 1 |
1 other study available for ondansetron and Brugada Syndrome
| Article | Year |
|---|---|
The effect of sevoflurane and ondansetron on QT interval and transmural dispersion of repolarization in children.
Topics: Adolescent; Anesthetics, Inhalation; Antiemetics; Arrhythmias, Cardiac; Brugada Syndrome; Cardiac Co | 2014 |